CXCL5 as a biomarker for early diagnosis and prognosis of sepsis: A comprehensive clinical evaluation
- 7 January 2025
- journal article
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110878
Abstract
No abstract availableKeywords
Funding Information
- Science Health Joint Medical Scientific Research Project of Chongqing
This publication has 33 references indexed in Scilit:
- Advances in sepsis biomarkers2024
- C-reactive protein and procalcitonin during course of sepsis and septic shockIrish Journal of Medical Science (1971 -), 2023
- Neutrophil, neutrophil extracellular traps and endothelial cell dysfunction in sepsisClinical and Translational Medicine, 2023
- Immunopathophysiology of human sepsisEBioMedicine, 2022
- Procalcitonin kinetics early after severe burn injury and its value in diagnosis of sepsisBurns, 2021
- Neutrophil recruitment by chemokines Cxcl1/KC and Cxcl2/MIP2: Role of Cxcr2 activation and glycosaminoglycan interactionsJournal of Leukocyte Biology, 2020
- CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic targetCancer Communications, 2020
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Lipid-Cytokine-Chemokine Cascade Drives Neutrophil Recruitment in a Murine Model of Inflammatory ArthritisImmunity, 2010
- CXCL5 Regulates Chemokine Scavenging and Pulmonary Host Defense to Bacterial InfectionImmunity, 2010